您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Sifalimumab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Sifalimumab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1006877-41-3
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议
100mg电议

产品名称
MEDI-545
MDX 1103
产品介绍
Sifalimumab (MEDI-545) 是一种anti-IFNα单克隆抗体,通过与多种干扰素-α 亚型结合来抑制异常的免疫活动。Sifalimumab 可用于系统性红斑狼疮 (SLE) 的研究。
生物活性

Sifalimumab (MEDI-545) is ananti-IFNαmonoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research[1][2].

体外研究
(In Vitro)

Sifalimumab (3-36 μg/well; 72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG[2].

Cell Viability Assay[2]

Cell Line:U-87MG cells and AGS lymphocytes
Concentration:3-36 μg/well
Incubation Time:72 hours
Result:Attenuated lymphocyte cytotoxicity triggered by IFN I (P<0.05).
体内研究
(In Vivo)

Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration[2].

Animal Model:Wild-type male BALB/c mice[2]
Dosage:30 mg/kg and 3 μg/g
Administration:Subcutaneous injection; 30 mg/kg and 3 μg/g
Result:Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P< 0.05).
Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration.
Attenuated the CD45 increase (P<0.05).
Clinical Trial
性状

Liquid

CAS 号

1006877-41-3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.